Advertisement

Springer Seminars in Immunopathology

, Volume 26, Issue 3, pp 329–341 | Cite as

Modulation of antitumor responses by dendritic cells

  • Johannes ViewegEmail author
  • Andrew Jackson
Original Article

Abstract

The discovery that dendritic cells (DC) play a key role in regulating antitumor immunity has prompted considerable efforts in developing DC-based cancer vaccines for use in clinical oncology. Early translational trials using antigen-loaded DC have established clear evidence of vaccine safety, and demonstrated bioactivity by stimulating immunological and even clinical responses in selected subjects. Despite these encouraging results, the vaccine-induced immune responses achieved to date are not yet sufficient to attain a robust and durable therapeutic effect in the cancer patient. Therefore, further improvements are required to enhance vaccine potency and optimize the potential for clinical success. This article presents a set of emerging concepts that, together, form a framework for a multi-pronged approach that will further enhance the efficacy of DC-based vaccination by either directly improving DC-mediated T cell activation or by inhibiting mechanisms that suppress the induction of an effective antitumor response. The clinical translation of these concepts will result in new opportunities to successfully modulate immune responses in clinical settings.

Keywords

Dendritic cells Antitumor immunity Immunosuppression Regulatory T cells CD4+ T cell immunity 

Notes

Acknowledgements

Some of the studies referred to in this manuscript were in part supported by grants from the National Cancer Institute (RO1 CA93910, R21 CA098446, RO1 CA89102), and the National Center for Research Resources, (MO1-RR-30), General Clinical Research Centers Program.

References

  1. 1.
    Alexandroff AB, Jackson AM, O’Donnell MA, et al (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353:1689Google Scholar
  2. 2.
    Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245Google Scholar
  3. 3.
    Bhardwaj N (2001) Processing and presentation of antigens by dendritic cells: implications for vaccines. Trends Mol Med 7:388Google Scholar
  4. 4.
    Bronte V, Serafini P, De Santo C, et al (2003) IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 170:270Google Scholar
  5. 5.
    Carson-Walter EB, Watkins DN, Nanda A, et al (2001) Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 61:6649Google Scholar
  6. 6.
    Chakraborty M, Abrams SI, Coleman CN, et al (2004) External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64:4328Google Scholar
  7. 7.
    Coggin JH Jr, Barsoum AL, Rohrer JW (1998) Tumors express both unique TSTA and crossprotective 44 kDa oncofetal antigen. Immunol Today 19:405Google Scholar
  8. 8.
    Cranmer LD, Trevor KT, Hersh EM (2004) Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 53:275Google Scholar
  9. 9.
    Dhodapkar MV, Steinman RM, Krasovsky J, et al (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233Google Scholar
  10. 10.
    Fong GH, Rossant J, Gertsenstein M, et al (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66Google Scholar
  11. 11.
    Fong L, Engleman EG (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245Google Scholar
  12. 12.
    Gramaglia I, Cooper D, Miner KT, et al (2000) Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand. Eur J Immunol 30:392Google Scholar
  13. 13.
    Greenberg PD, Kern DE, Cheever MA (1985) Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2 T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 161:1122Google Scholar
  14. 14.
    Hung K, Hayashi R, Lafond-Walker A, et al (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357Google Scholar
  15. 15.
    Jonuleit H, Kuhn U, Muller G, et al (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27:3135Google Scholar
  16. 16.
    Kalams SA, Walker BD (1998) The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188:2199Google Scholar
  17. 17.
    Kalinski P, Hilkens CM, Wierenga EA, et al (1999) T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20:561Google Scholar
  18. 18.
    Keilholz U, Weber J, Finke JH, et al (2002) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the society for biological therapy. J Immunother 25:97Google Scholar
  19. 19.
    Kjaergaard J, Tanaka J, Kim JA, et al (2000) Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 60:5514Google Scholar
  20. 20.
    Krieg AM (1999) Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1489:107Google Scholar
  21. 21.
    Kusmartsev S, Cheng F, Yu B, et al (2003) All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 63:4441Google Scholar
  22. 22.
    Kusmartsev S, Nefedova Y, Yoder D, et al (2004) Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172:989Google Scholar
  23. 23.
    Laderach D, Compagno D, Danos O, et al (2003) RNA interference shows critical requirement for NF-kappa B p50 in the production of IL-12 by human dendritic cells. J Immunol 171:1750Google Scholar
  24. 24.
    Lane P (2000) Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells. J Exp Med 191:201Google Scholar
  25. 25.
    Langenkamp A, Messi M, Lanzavecchia A, et al (2000) Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 1:311Google Scholar
  26. 26.
    Li Y, Wang MN, Li H, et al (2002) Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 195:1575Google Scholar
  27. 27.
    Lin KY, Guarnieri FG, Staveley-O’Carroll KF, et al (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21Google Scholar
  28. 28.
    Luft T, Jefford M, Luetjens P, et al (2002) Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E regulates the migratory capacity of specific DC subsets. Blood 100:1362Google Scholar
  29. 29.
    Martin E, O’Sullivan B, Low P, et al (2003) Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 18:155Google Scholar
  30. 30.
    MartIn-Fontecha A, Sebastiani S, Hopken UE, et al (2003) Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 198:615Google Scholar
  31. 31.
    Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991Google Scholar
  32. 32.
    Maxwell JR, Weinberg A, Prell RA, et al (2000) Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol 164:107Google Scholar
  33. 33.
    Melief CJ, Toes, RE, Medema, JP, et al (2000) Strategies for immunotherapy of cancer. Adv Immunol 75:235Google Scholar
  34. 34.
    Menges M, Rossner S, Voigtlander C, et al (2002) Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 195:15Google Scholar
  35. 35.
    Morse MA, Lyerly HK, Gilboa E, et al (1998) Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res 58:2965Google Scholar
  36. 36.
    Mumberg D, Monach PA, Wanderling S, et al (1999) CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 96:8633Google Scholar
  37. 37.
    Nair S, Boczkowski D, Moeller B, et al (2003) Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102:964Google Scholar
  38. 38.
    Nair S, McLaughlin C, Weizer A, et al (2003) Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 171:6275Google Scholar
  39. 39.
    Nair SK, Heiser A, Boczkowski D, et al (2000) Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6:1011Google Scholar
  40. 40.
    Nelson AR, Fingleton B, Rothenberg ML, et al (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135Google Scholar
  41. 41.
    Niethammer AG, Xiang R, Becker JC, et al (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8:1369Google Scholar
  42. 42.
    Ohshima Y, Tanaka Y, Tozawa H, et al (1997) Expression and function of OX40 ligand on human dendritic cells. J Immunol 159:3838Google Scholar
  43. 43.
    Olsen E, Duvic M, Frankel A, et al (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376Google Scholar
  44. 44.
    Onizuka S, Tawara I, Shimizu J, et al (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128Google Scholar
  45. 45.
    Pardoll DM, Topalian SL (1998) The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 10:588Google Scholar
  46. 46.
    Phan GQ, Yang JC, Sherry RM, et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372Google Scholar
  47. 47.
    Pulendran B, Palucka K, Banchereau J (2001) Sensing pathogens and tuning immune responses. Science 293:253Google Scholar
  48. 48.
    Qazilbash MH, Giralt SA, Champlin RE (2004) Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am 18:703Google Scholar
  49. 49.
    Qin Z, Blankenstein T (2000) CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12:677Google Scholar
  50. 50.
    Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474Google Scholar
  51. 51.
    Romani N, Reider D, Heuer M, et al (1996) Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 196:137Google Scholar
  52. 52.
    Rosenberg SA (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281Google Scholar
  53. 53.
    Ruedl C, Bachmann MF, Kopf M (2000) The antigen dose determines T helper subset development by regulation of CD40 ligand. Eur J Immunol 30:2056Google Scholar
  54. 54.
    Santulli-Marotto S, Nair SK, Rusconi C, et al (2003) Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res 63:7483Google Scholar
  55. 55.
    Schuler-Thurner B, Schultz ES, Berger TG, et al (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279Google Scholar
  56. 56.
    Seder RA, Ahmed R (2003) Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 4:835Google Scholar
  57. 57.
    Serafini P, De Santo C, Marigo I, et al (2004) Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 53:64Google Scholar
  58. 58.
    Shevach EM (2001) Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 193:F41Google Scholar
  59. 59.
    Shevach EM, McHugh RS, Piccirillo CA, et al (2001) Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 182:58Google Scholar
  60. 60.
    Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211Google Scholar
  61. 61.
    Siegel S, Wagner A, Schmitz N, et al (2003) Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol 122:911Google Scholar
  62. 62.
    Smith JW 2nd, Walker EB, Fox BA, et al (2003) Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 21:1562Google Scholar
  63. 63.
    Steinbrink K, Wolfl M, Jonuleit H, et al (1997) Induction of tolerance by IL-10-treated dendritic cells. J Immunol 159:4772Google Scholar
  64. 64.
    Su JM, Wei YQ, Tian L, et al (2003) Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res 63:600Google Scholar
  65. 65.
    Su Z, Vieweg J, Weizer A, et al (2002) Enhanced induction of telomerase-specific CD4+ T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 62:5041Google Scholar
  66. 66.
    Sutmuller RP, Duivenvoorde LM van, Elsas A van, et al (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823Google Scholar
  67. 67.
    Suzuki H, Wang B, Shivji GM, et al (2000) Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 114:135Google Scholar
  68. 68.
    Svane IM, Pedersen AE, Johnsen HE, et al (2004) Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 53:633Google Scholar
  69. 69.
    Testerman TL, Gerster JF, Imbertson LM, et al (1995) Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 58:365Google Scholar
  70. 70.
    Vonderheide RH, Domchek SM, Schultze JL, et al (2004) Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 10:828Google Scholar
  71. 71.
    Vonderheide RH, Hahn WC, Schultze JL, et al (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673Google Scholar
  72. 72.
    Wang T, Niu G, Kortylewski M, et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48Google Scholar
  73. 73.
    Weeks CE, Gibson SJ (1994) Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J Interferon Res 14:81Google Scholar
  74. 74.
    Wei YQ, Wang QR, Zhao X, et al (2000) Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 6:1160Google Scholar
  75. 75.
    Weinberg AD, Rivera MM, Prell R, et al (2000) Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164:2160Google Scholar
  76. 76.
    Wherry EJ, Teichgraber V, Becker TC, et al (2003) Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4:225Google Scholar
  77. 77.
    Wu T-C, Guarnier FG, Staveley-O’Carroll KF, et al (1995) Engineering an intracellular pathyway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 92:11671Google Scholar
  78. 78.
    Yu P, Spiotto MT, Lee Y, et al (2003) Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med 197:985Google Scholar
  79. 79.
    Zeis M, Siegel S, Wagner A, et al (2003) Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 170:5391Google Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Genitourinary Cancer Immunotherapy Program, Division of Urology, Department of SurgeryDuke University Medical CenterDurhamUSA

Personalised recommendations